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The application of modern
neurobiological techniques to the
pain field is rapidly increasing our
understanding of its pathophysiology
and this, in turn, is providing targets
for the development of new
therapies. We are poised on the brink
of a radical change in the treatment
of pain that will eliminate or replace
the current gold standards, namely
non-steroidal anti-inflammatory
drugs, opiates and local anesthetics
(or sodium channel blockers).
There are three main
manifestations of pain. It is an
essential physiological protective
mechanism, acting as an alarm
system that notifies the body of the
presence of some dangerous, noxious
stimulus in the environment. Also,
once tissue damage has occurred,
pain is a promoter of repair, by
creating a region of localized
hypersensitivity (known as
inflammatory pain) surrounding the
injured part. This hypersensitivity
minimizes movement of, or contact
with, the injury until healing has
occurred. Finally, there is so-called
‘neuropathic pain’, which does not
seem to have any beneficial function
but results from disturbances in
neural and non-neural cells that
provoke maladaptive changes in the
neurons of the sensory system. This
can cause spontaneous, persistent
pain and severe hypersensitivity.
Although pain is clearly a
subjective experience that is
generated within the brain and
integrally associated with emotional,
cognitive and learned behaviors, there
are two sites apart from the brain that
are actively involved in the early
stages of producing pain: the primary
sensory neurons in the periphery and
the central neurons in the dorsal horn
of the spinal cord with which they
make synaptic contact. It is
breakthroughs in our understanding
of the transduction mechanisms at
these two sites that are most likely to
lead to new therapies.
Pain and primary sensory neurons
Primary sensory neurons can be
divided into two broad classes: those
with peripheral terminals specialized
to transduce low-intensity peripheral
stimuli, which normally initiate
innocuous sensations; and those
sensory neurons (named nociceptors)
with peripheral terminals that have
high thresholds requiring noxious
stimuli to activate them and which
produce pain. This article will focus
on the nociceptor sensory neurons,
most of which are small-diameter,
unmyelinated C-fibers.
Nociceptors express many of the
molecules that have recently been
implicated in the pain activation and
sensitization process. These include
tetrodotoxin-resistant (TTXr)
sodium channels, and receptors for
prostaglandins, ATP, serotonin and
capsaicin, among many others.
Nociceptors fall into two distinct
classes, according to their
responsiveness to neurotrophic
factors. Nociceptors in one class, the
peptide-containing nociceptors,
synthesize, store and release the
neuropeptides substance P,
neurokinin A and CGRP (calcitonin
gene-related peptide). Members of
this peptide-containing class express
the TrkA neurotrophin receptor and
are responsive to nerve growth
factor (NGF).
Members of the second class of
nociceptor express fewer peptides;
they are distinguished by their
expression of a distinct surface lectin,
IB4, and the P2X3 subtype of
purinergic receptor. This class (in the
adult) expresses the c-ret growth
factor receptor and responds to the
GDNF (glial-derived neurotrophic
factor) family of growth factors.
Progress has been made recently
in dissecting out the molecular
pathways involved in the transduction
mechanisms of nociceptors. For
example, the vanniloid receptor VR1,
which is expressed only on
nociceptors, acts not only to recognize
noxious heat but also to recognize
capsaicin, the pungent ingredient in
chilli peppers. Recently, another
vanniloid receptor, VRL1, which is
expressed in myelinated nociceptors,
has been cloned and found to respond
only to very high levels of heat and
not to capsaicin.
Inflammation and pain
The contribution of sensory neurons
to inflammatory pain is complex.
Inflammation results in the
production of a soup of cytokines,
growth factors and inflammatory
mediators, including H+, K+, serotonin
(5-HT), bradykinin, histamine, ATP,
PGE2 (prostaglandin E2),
interleukin-1, TNFα (tumor necrosis
factor α) and NGF. Some of these (for
example, H+, ATP and 5-HT) directly
activate the nociceptors by interacting
with ligand-gated ion channels on the
terminal (see Figure 1). VR1 and
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Figure 1
The peripheral terminal of a nociceptor,
showing the various ligand-gated ion
channels and G protein-coupled receptors,
and the inflammatory mediators that bind
directly to them. Phosphorylation of the
TTX-resistant sodium channels (TTXr) is
driven by prostaglandin (PGE2) and 5-HT
acting on their receptors, which activate
protein kinase C (PKC) and protein kinase A
(PKA). This reduces the transduction
threshold of the terminal (known as
peripheral sensitization). The TTX-sensitive
sodium channel (TTXs) acts to conduct
action potentials out of the terminal to the
central nervous system.
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another class of receptors found on
nociceptors, the epithelial sodium
channel degenerins, are acid-sensing
ion channels (ASICs) that react to the
high levels of acidity in inflamed
tissues.
Other inflammatory mediators do
not directly activate the terminals
but sensitize them by reducing the
transduction threshold. This
sensitization of the terminals
involves phosphorylation of the
TTX-resistant sodium channels,
which increases inward current and
therefore terminal excitability. (The
TTX-resistant sodium channels
SNS/PN3 and SNS2/NaN are found
only on nociceptors and offer the
possibility of a selective block of
pain.) The phosphorylation of the
TTX-resistant sodium channels is
driven by prostaglandins, bradykinin
and 5-HT acting on their receptors,
which activates protein kinase C and
protein kinase A (see Figure 1).
TTX-sensitive sodium channels
(TTXs) act to conduct action
potentials out of the terminal to the
central nervous system.
Phenotypic plasticity of nociceptors
Although nociceptors are highly
specialized and differentiated, their
phenotype can change, both after
inflammation when there is an
increase in neurotrophins in the
inflamed tissue, and after nerve
injury when contact between the
cell body of the neurons and growth
factors in the target tissue is
disrupted. Neurotrophins act on
tyrosine kinase receptors that are
retrogradely transported to the cell
body, where they initiate complex
alterations in transcription —
including altered production of
neuropeptides, ion channels and
receptors — such that the functional
and signaling capacity of the
neurons alters (see Figure 2).
In the case of inflammation, for
example, levels of the peptide
substance P in cell bodies of
nociceptors increase. By contrast,
after nerve injury, levels of
substance P decrease but there is a
coincident increase of other
peptides, such as neuropeptide Y,
vasoactive intestinal polypeptide
(VIP) and galanin. Furthermore,
after inflammation some large-
diameter low-threshold sensory
neurons, which are normally not
involved in pain, begin to express
substance P. These neurons can now
communicate with spinal neurons
that express substance P receptors,
producing central actions similar to
those normally mediated by
nociceptors.
After peripheral nerve injury
there is both a damming-up of
TTX-resistant sodium channels at
the site of damage and an increase
in the transcription of
TTX-sensitive channels by the
injured neurons, which together
generate ectopic activity, sending
waves of spontaneous action
potentials to the spinal cord.
Pain and the central neurons
The heterogeneity of nociceptors,
and their accessibility, make them
an ideal target for therapy (see
Figure 3). Unfortunately, however,
many clinical persistent pain
conditions (such as neuropathic
pain) cannot be treated by blocking
messages from the primary sensory
neurons. In these situations, which
are triggered by intense and
persistent tissue or nerve injury, one
must deal with a reorganized spinal
cord dorsal horn, including
induction of new genes, sprouting of
primary sensory neurons, up-
regulation of a variety of
neurotransmitters, neurotransmitter
receptors and second messenger
systems. These changes cause a
prolonged increase in the
excitability of dorsal horn neurons.
These changes — collectively
referred to as ‘central sensitization’
— contribute to the generation of
pain by previously non-painful
stimuli (allodynia), to exacerbated
pain responses to previously painful
stimuli (hyperalgesia) and to
spontaneous pain conditions.
Central sensitization is not identical
to long-term potentiation (LTP) —
another form of neural modulation
responsible for memory storage in
the hippocampus — but they do
share many features. For example,
glutamate release from nociceptors
not only induces an acute pain
response via an action at AMPA
receptors but also triggers prolonged
changes via an action at NMDA
receptors. The mechanisms
involved — a calcium-triggered
post-translational phosphorylation of
NMDA receptors that increases the
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Figure 2
Transcriptional modulation in the cell body of a
peptide-containing nociceptor, induced by
signal molecules. Levels of nerve growth factor
(NGF) increase during inflammation and NGF
binds to TrkA receptors expressed on
nociceptors. The NGF–TrkA complex is
transported retrogradely to the cell body,
where it activates increased transcription of
neuropeptides (for example, substance P) and
ion channels (for example, TTXr and VR1).
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length of time channels are open
and removes the voltage-dependent
Mg2+ block — resemble LTP.
Antagonists of the NMDA receptor
can prevent or reverse the alteration
of pain processing produced by
tissue or nerve injury in animals,
and clinical trials with such drugs
have been encouraging. But, not
surprisingly, the most potent and
efficacious have unacceptable
psychotropic side-effects.
For this reason, interest has
turned to the downstream
consequences of activity at the
NMDA receptor. Numerous
behavioral and electrophysiological
studies in animals indicate that
blockade of a variety of second
messenger targets, including nitric
oxide synthase, protein kinase A and
protein kinase C can ameliorate
injury-induced persistent pain
states. Indeed, injury-induced
thermal and mechanical allodynia
can be significantly reduced in mice
with a deletion of the gene that
encodes the γ isoform of protein
kinase C (PKCγ).
In addition to undergoing
tremendous modification by local
spinal circuits, messages from the
primary sensory neurons are
profoundly influenced by
‘descending’ control systems that
originate in the brainstem. Indeed, it
is via these systems and via a direct
inhibitory action at the level of the
spinal cord that systemically
administered opiates can block pain.
It must also be emphasized that
there are many ‘ascending’ pathways
that carry the injury message to the
brain. Traditional views of a single
‘pain pathway’ that is synonymous
with the spinothalamic tract have
long been abandoned. Thus, the
experience of pain is produced by the
arrival in the brain of many inputs
from the spinal cord. Some inputs
enter sensory regions of the thalamus
and neocortex, others enter limbic
regions — notably the amygdala —
which contribute to the affective
(that is, emotional) component of the
pain experience. In fact, PET and
fMRI brain imaging studies indicate
that many other cortical and
subcortical regions are activated in
clinical conditions of persistent pain.
But although any discussion of the
pain experience must refer to the
contribution of the neocortex and
limbic regions, it is breakthroughs in
our understanding of the transduction
mechanisms in the peripheral
nociceptor and in the dorsal horn
circuits that process this information
that will lead to the development of
new treatments for persistent pain in
the foreseeable future.
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Figure 3
Some key circuits through which nociceptive
messages produced by injury are
transmitted to spinal cord, brainstem,
thalamus and neocortex (where the
perception of pain is ultimately generated).
The peripheral terminals of the two main
classes of nociceptor (colored red and
green) are targeted by mediators released
during tissue inflammation. Selective
antagonists to the receptors of these
mediators might prove beneficial. Because
the two nociceptor populations express
different neurotrophin receptors, their
selective regulation by neurotrophins might
also be possible. The central terminals of the
nociceptors, which express the same
receptors as are found in the peripheral
terminals, are also potential therapeutic
targets because they can be readily
accessed by spinal injection of drugs. Both
types of nociceptor use glutamate as their
excitatory neurotransmitter and thus AMPA
and NMDA receptor antagonists might
prove effective at the synapse in the dorsal
horn. The peptide-containing class of
nociceptor (red) makes direct synaptic
contacts with the outermost layer of the
dorsal horn (lamina I) and outer lamina II
(colored light gray), including projection
neurons that express the substance P
receptor and send axons to the brainstem
and thalamus. The non-peptide class of
nociceptor (green) terminates in the inner
part of lamina II (light gray), which contains
interneurons (colored blue), including some
that express PKCγ. Thus, drugs that
selectively interfere with the downstream
consequences of nociceptor activation might
also be effective after spinal injection. Note
that regulatory signals that arise from the
brainstem influence the outflow from the
spinal cord. They exert mixed inhibitory and
excitatory effects via an action of 5-HT and
norepinephrine on several receptor subtypes
in the spinal cord. This Figure focuses on the
periphery and spinal cord, because of their
accessibility to pharmacological
therapeutics. But the possibility of using
psychological approaches to regulating the
experience of pain at the level of the brain
cortex should not be ignored.
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